A Phase I, Open-label, Safety Study of Anti-inflammatory Therapy With Rilonacept in Adolescents and Adults With Type 1 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2014
At a glance
- Drugs Rilonacept (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms RID-A; RID1
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Feb 2013 Planned end date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.